Czech Republic Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most over-regulated markets in Europe, with new or innovative therapies facing significant delays before being able to enter the market. While the timelines are still outside the defined framework, the situation is much…
Czech Republic A cross-industry push for better and broader access to innovative treatments is underway in the Czech Republic. Ripe for reform is the country’s orphan drug legislation as no standard pathway for their assessment, pricing and reimbursement currently exists. [For cancer treatment the country has been] quite successful in moving…
Czech Republic Among the seven insurance funds in the Czech Republic, VZP is the largest with six million clients and the widest network of health service providers. David Šmehlík, the organisation’s deputy director, discusses its new focus on creating a patient-centric healthcare system based on quality and accessibility, the government’s primary care…
See our Cookie Privacy Policy Here